

Original Research Article

The Role of Potassium to Creatinine Ratio as Diagnostic Test in Pre-Eclampsia

Gaith Kamil Jawad^{1*} Haydar Hashim Al-Shalah² Milal Muhammad Al-Jeborry²
¹Babylon Teaching Hospital for Gynecology and Pediatrics, Hilla, IRAQ
²College of Medicine, University of Babylon, Hilla, IRAQ

*E-mail: gaithkamil@yahoo.com

Accepted 19 September, 2017

Abstract

Pre-eclampsia is defined as hypertension associated with proteinuria arising *de novo* after the 20th week of gestation in a previously normotensive woman and resolving completely by the 6th postpartum week. It is a major cause of morbidity and mortality during pregnancy. There are many ways to diagnose the disease, based on clinical diagnosis and conduct some tests; measurement of the amount of protein in urine sample that had been collected for a period of twenty-four hours. Evaluate urinary K⁺ to creatinine ratio as a diagnostic and screening test in PE.

Our study was carried out at Babylon Teaching Hospital for Gynecology and Pediatrics, in Babylon Province, Hilla City from February-August- 2016. The total number of all cases was 88,44 among them women with normal pregnancy, 44 cases with PE. Every patient was sent for urinary K⁺ and creatinine in spot urine which both were determined by ion selective electrode and Moorehead and Briggs derived O-Cresol Pthalien Complexone method respectively, and the ratio K⁺ to creatinine were calculated. Data are given as mean \pm SD, and t-test were used as statistical method to test the result. Urinary K⁺/creatinine ratio was significantly higher in patients with pre-eclampsia compared to control groups (*P value* <0.01). The sensitivity of urinary K⁺/creatinine ratio to detect PE was (77%) while, its specificity was (68%).

Urinary K⁺/creatinine ratio is significantly increase in preeclamptic women.

Key Words: Pre-eclampsia, urinary Potassium, urinary Creatinine, K⁺ /creatinine ratio.

الخلاصة

تسم الحمل (ما قبل الأرتعاج) هو ارتفاع ضغط الدم المرتبط بارتفاع البروتين بالإدرار بعد الأسبوع ٢٠ من الحمل في المرأة ذات ضغط الدم الطبيعي سابقاً و الذي ينتهي تماماً قبل الأسبوع السادس بعد الولادة. وهو سبب رئيسي للوفاة أثناء الحمل. هناك طرق كثيرة لتشخيص المرض، تعتمد على التشخيص السريري وإجراء بعض الفحوصات وفحص مسحي يتضمن قياس كمية الزلال الموجود في نموذج إدرار تم جمعه لمدة أربع وعشرين ساعة.

الغرض من الدراسة هو حساب نسبة البوتاسيوم إلى الكرياتينين في نموذج إدرار عشوائي كفحص مسحي وتشخيصي لمرض ما قبل الإرتعاج. تم إجراء هذه الدراسة على مجموعة من المرضى في مستشفى بابل التعليمي للنسائية والأطفال، في محافظة بابل، مدينة الحلة. وقد تم جمع العينات من شباط ٢٠١٦ حتى آب ٢٠١٦. شملت الدراسة مقارنة الحالة ل ٨٨ امرأة، أربع وأربعون حالة مرضية تم تشخيص إصابتهم بمرض ما قبل الإرتعاج والأربع واربعين الأخرى من نساء حوامل صحيحة وقد تم أخذ عينات إدرار عشوائية من كل الحالات لغرض إيجاد البوتاسيوم والكرياتينين في الإدرار وبعد ذلك حساب النسبة بينهما وقد تم إجراء عمليات إحصائية متعددة للحصول على النتائج وقد وجد مايلي: نسبة البوتاسيوم إلى الكرياتينين كانت مرتفعة بشكل معنوي في المرضى الذين يعانون من تسم الحمل مقارنة بالأصحاء قيمة ($P < 0.01$). وكانت قيمة الخصوصية (٧٧%) بينما القيمة النوعية كانت (٦٨%).

الكلمات المفتاحية: تسم الحمل ، البوتاسيوم في الإدرار ، الكرياتينين في الإدرار ، البوتاسيوم إلى الكرياتينين.

Introduction

Pre-eclampsia (PE) is defined as hypertension associated with proteinuria arising de novo after the 20th week of gestation in a previously normotensive woman and resolving completely by the 6th postpartum week. It is a leading cause of fetal and maternal morbidity and mortality [1].

Pre-eclampsia is an idiopathic disorder of pregnancy. Recent studies indicate that over 63000 women die worldwide each 3year due to PE and its complications, with 98% of them occurring in developing countries. In UK, PE is the second most common cause of both direct maternal death and perinatal loss, responsible for the death of six to nine women annually and over 175 babies. More than 10% of women will have PE in their first pregnancy and although the majority of these will have successful pregnancy outcomes, the conditions can give rises to severe multisystem complications including cerebral haemorrhage, hepatic and renal impairment and respiratory compromise. The development of strategies to prevent and treat the disorder has been challenging due to an incomplete understanding of the underlying pathogenesis [2-5].

Symptoms which predicate imminent eclampsia including headache, visual disturbances, epigastric and right upper abdominal pain or may be asymptomatic [6]. Signs is included elevation of blood pressure, fluid retention, brisk reflexes and uterine and fetal size may be feel smaller for gestational age [7].

A two-stage model of PE has been proposed as a means of addressing its pathophysiology. The first was placental perfusion reduced in PE. Evidence for this came originally from clinical findings. The second was The clinical features of PE appear to arise from a generalized systemic inflammatory response, of which endothelial dysfunction is a prominent components. Several serum markers of endothelial activations are altered in women with PE, including

Von Willebrand antigen, cellular fibronectin, and endothelin [8-12].

The relation between two stages is completed before the 20th week and prior to the appearance of clinical signs. In the second and third trimesters of pregnancy, the placenta requires increasing access to the maternal blood supply. As a result of the first stage, leading to a reduced uterine perfusion, the placenta becomes increasingly hypoxic. This hypoxic and dysfunctional placenta is considered to release factors into the maternal circulation that eventually cause the clinical features of PE. These released factors act as the linkage between the two stages and their identifications could hopefully enable the development of therapies for prevention of the clinical stages development [13,14].

Potassium (K^+) is an essential mineral micronutrient and the main intracellular ion for all types of cells. It is important in maintaining fluid and electrolyte balance in the bodies of humans and animals [15]. The body in steady state K^+ balance with K^+ intake (normally 60-80 mmol/day) equal to K^+ excretion. The kidney excrete the bulk of ingested K^+ (renal excretion 50- 65 mmol /day, stool 10-15 mmol/day, and small amount is lost via the skin in sweat). Urinary K^+ excretion rises in response to increased intake. Under normal circumstances, 180 L plasma are filtered per day, resulting in the entry of 720 mmol K^+ in the lumen of the nephron. The majority of the filtered K^+ (around 500 mmol) is reabsorbed in the proximal tubule. The control of K^+ secretion occurs primarily in the principle cells of the cortical collecting duct. K^+ secretion is dependent on the delivery of Na^+ and water to the cortical collecting duct and on the action of hormone aldosterone. Aldosterone increases Na^+ reabsorption from the lumen and promotes K^+ secretion into the lumen, restoring electrical neutrality [16-18].

Creatinine is formed from creatine and creatine phosphate in muscle and is excreted into the plasma at a constant rate related to muscle mass. Plasma creatinine

is inversely related to GFR and, although an imperfect measure, it is commonly used to assess renal filtration function. Small amounts of creatinine are secreted by the proximal tubule and reabsorbed by the renal tubules [19-21]. A creatinine urine test can measure amount of creatinine in urine. It can be done on its own or with other tests that establish the amount of other substances in the urine [22].

Materials and Methods

This prospective study was carried at Babylon Teaching Hospital for Maternity and Children, Babylon Province, Hilla City from February 2016 till August 2016. 88 cases were divided into two groups: 44 of them were patients diagnosed with PE in the 2nd and 3rd trimester and the other 44 normal pregnancy.

The following inclusion criteria were followed: pre-eclampsia was diagnosed by blood pressure elevation equal to or more than 140/90 mm Hg in combination with proteinuria ++ and/or oedema after 20 weeks gestation in previously normotensive non proteinuric patients. Their ages ranges from 21 – 30 years, the gestational ages from 21 – 37 weeks..

The exclusion criteria were: Age over 35 years, multiple pregnancy, history of essential hypertension, diabetes mellitus, renal disease, hepatic disease, blood disorder, epilepsy and other medical disease, body mass index > 30, and any history of drug intake other than supplement.

Body mass index (BMI) was calculated as: $BMI = \text{Weight (kg)} / \text{Height (m}^2\text{)}$ [23]. Blood pressure was recorded in the study in the sitting position with cuff that is large enough for the subjects arm on at least 2 occasions 6 hours apart. Proteinuria was diagnosed by collecting clean catch mid-stream urine sampled in clean dry container then urine protein was determined using the strips [Albustix] reading at 2+ [1 gm/l] or more was considered to be positive result for protein urea, the urine samples were centrifuged at 1000 g for approximately 5 minutes then the supernatant was taken to estimate of potassium and creatinine, by using electrolyte analyzeris dependent upon the ion selective electrode principle, and spectrophotometric method Jaffe reaction respectively [24,25]. K^+ /creatinine ratio was calculated by the following equation: $\text{Result of } K^+ \text{ (mmol/L)} / \text{Result of creatinine (g/L)}$. Unit of the ratio: mmol/g. Data are given as mean \pm SD, and t-test were used as statistical method to test the result. All analyses were performed using commercially available software (SPSS version 20th). P-value of <0.01was considerede to be statistically significant.

Results

Table 1 showed the mean differences of socio-demographic characteristic including (age, body mass index and gestational age) between to studied groups (patients with PE and control group).

Table 1: The Mean Differences of Socio-Demographic Characteristics in Studied Groups

Variable	Study groups	No.	Mean \pm SD	P-value
Age (years)	preeclampsia	44	26.18 \pm 2.67	> 0.01
	control group	44	25.75 \pm 2.91	
BMI (kg/m ²)	preeclampsia	44	28.22 \pm 1.11	> 0.01
	control group	44	28.56 \pm 1.41	
Gestational age (weeks)	preeclampsia	44	29.79 \pm 3.23	> 0.01
	control group	44	28.77 \pm 4.95	

**p* value < 0.01 was significant

There were no significant differences between means of age, body mass index and gestational age (*P*. value > 0.01).

Table 2: The Mean Differences of Systolic and Diastolic Blood Pressure in Studied Groups.

Variable	Study groups	No.	Mean \pm SD	P-value
Systolic blood pressure (mmHg)	preeclampsia	44	147.5 \pm 8.03	< 0.01*
	control group	44	123.59 \pm 5.14	
Diastolic blood pressure (mmHg)	preeclampsia	44	89.31 \pm 5.23	< 0.01*
	control group	44	61.13 \pm 3.38	

**p* value < 0.01 was significant

Table-2 showed that there were significant differences between means of systolic and diastolic blood pressure in studied groups.

Figure-1 shown there were statistically significant difference between the mean of K⁺/creatinine ratio (mmol/g) between controls (77.88 \pm 9.16) and patients (84.51 \pm 4.21) (**P**< **0.01**).




Figure 1: Mean Differences of Potassium to Creatinine Ratio (mmol/g) in Studied Groups.

Table-3 showed the sensitivity and specificity of potassium to creatinine ratio findings in comparison to clinical diagnosis. The sensitivity of potassium to creatinine ratio to detect preeclampsia was (77%) that mean the positive result of potassium to creatinine ratio (81.2 mmol/g

or more) was able to detect approximately (77%) of patients with PE correctly meanwhile, its specificity was (68%) that mean the negative result of potassium to creatinine ratio was able to detect approximately (68%) of those women with normal blood pressure correctly.

Table 3: Comparison of Potassium to Creatinine Ratio Findings Versus Clinical Diagnosis of Preeclampsia

Potassium to creatinine ratio findings versus Clinical Diagnosis		Clinical diagnosis		Total
		Preeclampsia	Normal pregnancy	
Potassium to creatinine ratio (mmol/g)	positive	34	14	48
	negative	10	30	40
	Total	44	44	88

Sensitivity = $(34/44) \times 100 = 77.3\%$

Specificity = $(30/44) \times 100 = 68.2\%$

Overall accuracy = $(34+30/88) \times 100 = 72.7\%$

Discussion

Urine collection is more reliable than other methods to assess potassium consumption in this study, the ratio of K⁺/creatinine was measured and the results that emerged showing an increased in potassium excretion in patients with PE compared with normotensive pregnant women. This might be due to activation of rennin angiotensin system that lead to increased

production of aldosterone and consequently increase in K⁺ excretion in

urine. Increased dietary intake of vegetables and fruit (rich potassium intake) that cause increase excretion of K⁺ in urine [26].

Using a cutoff value of urinary K⁺/creatinine ratio at 81.2 mmol/g, the

sensitivity was 77% and specificity was 68%. So the K⁺/creatinine ratio in patient with PE has low sensitivity and specificity so it can't be used as a diagnostic or screening test.

Conclusion

Urinary K⁺/creatinine ratio is significantly increased in pre-eclamptic women, but it can't be used as a diagnostic or screening test.

References

1. Elisabeth B, Lars J, Tom L. Pre pregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. *British Medical Journal* 2007; 335: 978-981.
2. World Health Organization. Trends in Maternal Mortality: 1990 to 2008. Geneva: WHO, 2010.
3. Dennis AT, Mulligan SM. Analgesic requirements and pain experience after caesarean section under neuraxial anesthesia in women with preeclampsia. *Hypertens Pregnancy* 2014;41:1-9.
4. Waugh J, Smith M. Hypertensive Disorders. *Dewhurst's Textbook of Obstetrics & Gynecology*, 8th Ed. John Wiley & Sons Ltd, India 2012; Ch 11: pp 101-110.
5. Abbas M. The Role of Trace and Ultratrace Elements in Pathogenesis of Pre-eclampsia, Babylon: University of Babylon 2015. 1 pp. Dissertation.
6. Symond EA. and Symond LM. *Essential obstetrics and Gynecology*, Ed 4th. Churchill Livingstone c- Philadelphia 2004;163-168.
7. James MF, Dyer RA. Prevention of Peri-Induction Hypertension in Pre-Eclamptic Patients. *Anesth Analg* 2015;121:1678-1679.
8. Abalos E, Cuesta C, Carroli G, Qureshi Z, Widmer M, Vogel J, *et al.* Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multi-country Survey on Maternal and Newborn Health. *BJOG* 2014;121:14-24.
9. Arain N, Mirza WA, Aslam M. Review- Vitamin D and the prevention of preeclampsia: A systematic review. *Pak J Pharm Sci.* 2015; 28: 1015-21.

10. Gilbert JS, Ryan MJ, Lamarca BB, *et al.* Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. *Am J Physiol Heart Circ Physiol* 2014; 294: 541-548.
11. Uyar I, Kurt S, Demirtas O, Gurbuz T, Aldemir OS, Keser B. *et al.* The value of uterine artery Doppler and NT-proBNP levels in the second trimester to predict preeclampsia. *Arch Gynecol Obstet.* 2015; 291:1253-1258.
12. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. *European J obstetrics gynecology reproductive biology* 2013; 170: 1-7.
13. Park HJ, Shim SS, Cha DH. Combined Screening for Early Detection of Pre-Eclampsia. *Int J Molec Sci.*, 2015; 16: 17952-17974.
14. Masoudian P, Nasr A, de Nanassy J, *et al.* Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and meta-analysis. *Am J Obstet Gynecol* 2016; 214: 328.
15. Hanna R, Wheeler S, Murray H. *Sodium and Potassium in Health and Disease, Metal Ions in Life Sciences.* Springer 2013; 2 (13): 29-47.
16. Hughes J, Jefferson A. *Clinical Chemistry made easy*, Inter. Ed. Churchill Livingstone Elsevier 2008; Ch 1: pp 1-19.
17. Holbrook JT, Patterson KY, Bodner JE, Douglas LW, Veillon C, Kelsay JL, *et al.* Sodium and potassium intake and balance in adults consuming self-selected diets. *Am J Clin Nutr* 1984; 40: 786-793.
18. Hughes J, Jefferson A. *Clinical Chemistry made easy*, Inter. Ed. Churchill Livingstone Elsevier 2008; Ch 2: pp 22-36.
19. Bishop L, Fody P, Schoeff E. *Clinical Chemistry (Technique, Principle, Correlation)*, Ed 7th. Lippincott Williams & Wilkins, a Wolters Kluwer Business, China 2013; Part 2, Sec 11: pp 273-276.
20. John W, Marek H. *Medical Biochemistry*, Ed 4th. Saunders Elsevier Ltd, China 2014; Ch 23: pp 309-319.
21. Rahn KH, Heidenreich S, Bruckner D. How to assess glomerular function and damage. *J Hypertens* 1999; 17:309-317.

22. Manjunath G, Sarnak MJ, Levey AS. Estimating the glomerular filtration rate, Do's and doesn't for assessing kidney function. *Postgrad Med* 2001; 110:55–62.
23. Institute of Medicine. *Weight Gain During Pregnancy: Reexamining the Guidelines*. Washington 2009.
24. Oesch U, Ammann D, Simon W. Ion-selective membrane electrodes for clinical use. *Clin Chem* 1986; 32:1448–1459.
25. Varley H, Gowenlock A, Bell M. *Practical Clinical Biochemistry (General Topic and Commoner Tests)*, Ed 5th, Vol 1. William Heinmann medical books Ltd, India 1991; Ch 17: pp 451-488.
26. Molina MB, Cunha RS, Herkenhoff FL, Mill JG. Hypertension and salt intake in an urban population. *Rev Saúde Pública* 2003; 37: 743-750.